



Company name: KYORIN Holdings, Inc.
Representative: Masahiro Yamashita
Representative Director, President
(Securities Code: 4569, TSE 1st Sec.)

Release of **Flutiform**[®] 50 Aerosol - 120 inhalations, **Flutiform**[®] 125 Aerosol - 120 inhalations, a combination drug for asthma treatment

TOKYO, JAPAN (December 1, 2014) - Kyorin Pharmaceutical Co., Ltd. (“Kyorin”) (Head office: Chiyoda-ku, Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc., announced the release of **Flutiform**[®] 50 Aerosol - 120 inhalations and **Flutiform**[®] 125 Aerosol - 120 inhalations, both of which are for 30-day supplies. This was intended to synchronize with the timing of when prescription longer than two weeks is permitted as one year has passed since the launch of **Flutiform**[®] in November 2013.

The drug has been reputed as a therapy beneficial to the improvement of respiratory functions and control of bronchial asthma. The release of the limitation for prescription will help the drug further contribute to improvement of the QOL in still more patients with asthma.

Kyorin will further contribute to patient treatment by enhancing the product lineup of its priority area of respiratory products and by continuing to provide up-to-date information.

The sales of the drug is factored in consolidated forecast for the fiscal year ending March 31 2015 , which disclosed on November 4 2014.

(New product information)

Brand name : **Flutiform**[®] 50 Aerosol - 120 inhalations
Flutiform[®] 125 Aerosol - 120 inhalations

Active ingredient : fluticasone propionate (inhaled corticosteroid)
formoterol fumarate hydrate (a long-acting inhaled β 2 agonist)

Indication : Bronchial asthma (when a combination of an inhaled steroid and a long-acting Inhaled β 2 agonist is necessary)

Dosage and administration:
Adults should use **Flutiform**[®] 50 Aerosol (50 μ g fluticasone propionate and 5 μ g formoterol fumarate) 2 times per day (2 inhalations per application). Depending on the symptoms, **Flutiform**[®] 125 Aerosol (125 μ g fluticasone propionate and 5 μ g formoterol fumarate) can be used 2 times per day (2 to 4 inhalations per application).

NHI price : ¥5,780.70 per an inhaler (**Flutiform**[®] 50 Aerosol - 120 inhalations)
¥6,759.10 per an inhaler (**Flutiform**[®] 125 Aerosol - 120 inhalations)

Date of Drug Price Listing : November 28, 2014
Date of initial marketing in Japan : December 1, 2014

(New product photo)

